TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, November 4, 2024, at 8:30 AM ET to discuss their third quarter 2024 financial results and provide a business outlook. The call will be hosted by Chairman and CEO Michael S. Weiss. Financial results will be released before the call. Participants can join via phone (1-877-407-8029 U.S., 1-201-689-8029 international) or watch the live webcast on the company's website. An audio recording will be available for 30 days after the call.
TG Therapeutics (NASDAQ: TGTX) ha fissato una conference call per lunedì 4 novembre 2024, alle 8:30 AM ET, per discutere i risultati finanziari del terzo trimestre 2024 e fornire una previsione aziendale. La chiamata sarà condotta dal Presidente e CEO Michael S. Weiss. I risultati finanziari saranno comunicati prima della chiamata. I partecipanti possono unirsi tramite telefono (1-877-407-8029 U.S., 1-201-689-8029 internazionale) o guardare la diretta sul sito web dell'azienda. Una registrazione audio sarà disponibile per 30 giorni dopo la chiamata.
TG Therapeutics (NASDAQ: TGTX) ha programado una conferencia telefónica para el lunes 4 de noviembre de 2024, a las 8:30 AM ET, para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una perspectiva empresarial. La llamada será presentada por el Presidente y CEO Michael S. Weiss. Los resultados financieros se publicarán antes de la llamada. Los participantes pueden unirse por teléfono (1-877-407-8029 EE.UU., 1-201-689-8029 internacional) o ver la transmisión en vivo en el sitio web de la empresa. Una grabación de audio estará disponible durante 30 días después de la llamada.
TG Therapeutics (NASDAQ: TGTX)는 2024년 11월 4일 월요일 오전 8시 30분 ET에 2024년 3분기 재무 결과에 대해 논의하고 사업 전망을 제공하기 위해 컨퍼런스 콜을 예정했습니다. 이 콜은 의장 겸 CEO인 Michael S. Weiss가 주최합니다. 재무 결과는 콜 전에 발표될 예정입니다. 참가자는 전화(1-877-407-8029 미국, 1-201-689-8029 국제)를 통해 참여하거나 회사 웹사이트에서 생중계를 시청할 수 있습니다. 콜 후 30일 동안 오디오 녹음이 제공됩니다.
TG Therapeutics (NASDAQ: TGTX) a prévu une conférence téléphonique pour le lundi 4 novembre 2024, à 8h30 ET, afin de discuter de leurs résultats financiers du troisième trimestre 2024 et de fournir des perspectives commerciales. L'appel sera animé par le Président et CEO Michael S. Weiss. Les résultats financiers seront publiés avant l'appel. Les participants peuvent se joindre par téléphone (1-877-407-8029 É.-U., 1-201-689-8029 international) ou regarder la diffusion en direct sur le site de l'entreprise. Un enregistrement audio sera disponible pendant 30 jours après l'appel.
TG Therapeutics (NASDAQ: TGTX) hat eine Telefonkonferenz für Montag, den 4. November 2024, um 8:30 Uhr ET angesetzt, um über ihre finanziellen Ergebnisse des dritten Quartals 2024 zu sprechen und einen Geschäftsausblick zu geben. Die Konferenz wird von Geschäftsführer und CEO Michael S. Weiss geleitet. Die finanziellen Ergebnisse werden vor der Konferenz veröffentlicht. Die Teilnehmer können telefonisch (1-877-407-8029 USA, 1-201-689-8029 international) teilnehmen oder die Live-Übertragung auf der Unternehmenswebsite ansehen. Eine Audioaufnahme wird 30 Tage nach der Konferenz verfügbar sein.
- None.
- None.
Conference call to be held Monday, November 4, 2024, at 8:30 AM ET
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When will TG Therapeutics (TGTX) report Q3 2024 earnings?
How can I listen to TG Therapeutics (TGTX) Q3 2024 earnings call?
Will TG Therapeutics (TGTX) Q3 2024 earnings call be recorded?
